David Z. Cherney
David Z. Cherney
Professor of Medicine, University of Toronto
Verified email at
Cited by
Cited by
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
DZI Cherney, BA Perkins, N Soleymanlou, M Maione, V Lai, A Lee, ...
Circulation 129 (5), 587-597, 2014
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
CP Cannon, R Pratley, S Dagogo-Jack, J Mancuso, S Huyck, ...
New England Journal of Medicine 383 (15), 1425-1435, 2020
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
HJL Heerspink, BA Perkins, DH Fitchett, M Husain, DZI Cherney
Circulation 134 (10), 752-772, 2016
Empagliflozin in patients with chronic kidney disease
EMPA-Kidney Collaborative Group
New England Journal of Medicine 388 (2), 117-127, 2023
Sotagliflozin in patients with diabetes and chronic kidney disease
DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ...
New England Journal of Medicine 384 (2), 129-139, 2021
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
DK McGuire, WJ Shih, F Cosentino, B Charbonnel, DZI Cherney, ...
JAMA cardiology 6 (2), 148-158, 2021
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
DZI Cherney, BA Perkins, N Soleymanlou, R Har, N Fagan, OE Johansen, ...
Cardiovascular diabetology 13, 1-8, 2014
Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials
Y Lytvyn, P Bjornstad, JA Udell, JA Lovshin, DZI Cherney
Circulation 136 (17), 1643-1658, 2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the …
DZI Cherney, B Zinman, SE Inzucchi, A Koitka-Weber, M Mattheus, ...
The lancet Diabetes & endocrinology 5 (8), 610-621, 2017
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
HJL Heerspink, M Kosiborod, SE Inzucchi, DZI Cherney
Kidney international 94 (1), 26-39, 2018
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
MC Thomas, DZI Cherney
Diabetologia 61, 2098-2107, 2018
Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials
J Rosenstock, J Marquard, LM Laffel, D Neubacher, S Kaspers, ...
Diabetes care 41 (12), 2560-2569, 2018
Serum urate lowering with allopurinol and kidney function in type 1 diabetes
A Doria, AT Galecki, C Spino, R Pop-Busui, DZ Cherney, I Lingvay, ...
New England Journal of Medicine 382 (26), 2493-2503, 2020
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial
BA Perkins, DZI Cherney, H Partridge, N Soleymanlou, H Tschirhart, ...
Diabetes care 37 (5), 1480-1483, 2014
Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk
Y Yinon, JCP Kingdom, A Odutayo, R Moineddin, S Drewlo, V Lai, ...
Circulation 122 (18), 1846-1853, 2010
Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
CCJ Dekkers, S Petrykiv, GD Laverman, DZ Cherney, RT Gansevoort, ...
Diabetes, Obesity and Metabolism 20 (8), 1988-1993, 2018
Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging
K Kidokoro, DZI Cherney, A Bozovic, H Nagasu, M Satoh, E Kanda, ...
Circulation 140 (4), 303-315, 2019
Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature
D Cherney, S Straus
Journal of general internal medicine 17 (12), 937-945, 2002
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, ...
The Lancet 400 (10365), 1788-1801, 2022
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
DZI Cherney, ME Cooper, I Tikkanen, E Pfarr, OE Johansen, HJ Woerle, ...
Kidney international 93 (1), 231-244, 2018
The system can't perform the operation now. Try again later.
Articles 1–20